News

FDA and NIH Enter Rare Neurodegenerative Diseases Partnership

September 21, 2022

The Public-Private Partnership for Rare Neurodegenerative Diseases will work to enhance understanding and develop treatments for rare neurodegenerative diseases.

FDA Approves Bluebird Bio’s $3 Million CALD Treatment

September 21, 2022

FDA granted accelerated approval to Skysona (elivaldogene autotemcel), which is designed to slow the progression of neurologic dysfunction in adolescents with CALD.

Lonza Expands HPAPI Multipurpose Suite

September 21, 2022

Lonza has expanded its HPAPI multipurpose suite for payload-linker manufacturing.

Boehringer Ingelheim Adopts Virtuosi VR Education Platform

September 21, 2022

Boehringer Ingelheim will use Virtuosi to train employees at three aseptic sites across its network.

Clinical Trial Modernization Raises FDA Compliance Issues

September 20, 2022

Regulatory officials are addressing challenges in ensuring that clinical data can be relied on in making regulatory decisions.

CytoReason Announces Expanded Collaboration Deal with Pfizer

September 20, 2022

CytoReason has announced an expanded collaboration deal with Pfizer to deliver AI for drug discovery and development.

EC Approves Lupkynis for Treatment of Active Lupus Nephritis

September 20, 2022

Otsuka announced that the EC has approved Lupkynis as the first oral treatment for active lupus nephritis.

Civica to Invest $27.8 Million in New Testing Facility

September 19, 2022

Civica is expanding in the greater Richmond-Petersburg region and investing $27.8 million in a new testing facility.

Novo Nordisk and Microsoft Collaborate to Accelerate Drug Discovery and Development

September 19, 2022

Novo Nordisk and Microsoft are collaborating to accelerate drug discovery and development using big data and artificial intelligence.

Ensysce Biosciences and Quotient Sciences Announce Partnership

September 19, 2022

Ensysce Biosciences and Quotient Sciences are partnering to develop and test Ensysce’s novel opioid designed to prevent abuse and overdose.